Nanoparticle Platforms for Drug and Gene Delivery

S. Chen

Keywords: drug, gene, delivery, nanoparticle, nanoplatforms


Nanotheranostic methods combine therapeutic and diagnostic/monitoring capabilities within individual, highly targeting nanocarriers (also called nanoplatforms). There have been various nanocarriers developed so far for nanotheranostics—namely, polymer conjugations, dendrimers, micelles, liposomes, metallic and other inorganic nanoparticles, carbon nanotubes, and nanoparticles of biodegradable polymers—for sustained, controlled and targeted co-delivery of diagnostic and therapeutic agents for enhanced theranostic benefits with fewer side effects. Properly designed theranostic nanomedicines can achieve wide systemic circulation, evade host defenses and deliver drug and diagnostic agents to targeted sites for diagnosis and treatment at cellular and molecular levels. These therapeutic/diagnostic agents are formulated using versatile, standardized theranostic platforms that can be customized by conjugation to biological ligands for targeting. Nanotheranostics can also enable stimulus-responsive release, synergetic and combination therapy, siRNA co-delivery, multimodal therapies, oral delivery, delivery across the blood-brain barrier, and escape from intracellular autophagy. This talk will highlight our recent progress in applying hyaluronic acid-5β-cholanic acid conjugate (HACA) based nanoformulas to deliver both lipophilic drug molecules and siRNA for the treatment of multidrug resistant tumors.